PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/PVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in type 2 diabetes (T2DM) management discusses how to individualize treatment with GLP-1 RAs to improve outcomes for patients. Upon completion of this activity, participants should be better able to: Apply evidence-based treatment recommendations for GLP-1 RAs based on clinical trial results evaluating glycemic and extra-glycemic (eg, cardiovascular risk reduction, weight education) outcomes in patients with T2DM, Identify potential barriers to use (ie, mode of administration, adverse events) for current and emerging GLP-1 RAs, Engage in patient-centered discussions about the benefits and risks of using GLP-1 RAs to personalize management of T2DM.

Go online to PeerView.com/URQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs). Upon completion of this activity, participants will be able to: Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE, Assess the quality and validity of the evidence collected as part of real-world studies comparing the DOACs with warfarin in patients with VTE (eg, efficacy, safety, cost-effectiveness, quality of life), Incorporate RWE into clinical decision-making for patients with VTE to design individualized treatment plans, especially for patients who may not be well represented in randomized clinical trials.

Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.

Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.

Go online to PeerView.com/KXM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this case-based activity, experts in oncology and primary care examine how to best integrate future blood-based cancer screening tools into clinical practice in order to reduce cancer-related morbidity and mortality. Upon completion of this activity, participants should be better able to: Explain the scientific principles behind cfDNA-based liquid biopsy as a tool for early cancer screening, including the strengths and limitations of liquid biopsy compared with those of conventional screening methods, Identify the diagnostic/screening role of novel cfDNA-based screening assays for early cancer detection in the primary care setting, Adapt current cancer screening protocols based on recent evidence on emerging cfDNA-based multicancer screening assays in order to improve sensitivity, specificity, and tumor localization accuracy, Employ patient-centered strategies to integrate novel cancer screening methodologies in the primary care setting, including as part of educational and screening protocols.

Go online to PeerView.com/TWX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in cardiovascular medicine discuss the benefits of telemedicine when screening and caring for patients with nonvalvular atrial fibrillation (NVAF). Upon completion of this activity, participants will be able to: Identify the benefits of using telemedicine and remote care services to diagnose and manage patients with NVAF, Describe ways in which telemedicine and remote care services can be used to increase patient awareness about the risks of NVAF and overcome healthcare disparities to improve healthcare delivery for patients with untreated NVAF, Operationalize best practices to design processes and procedures for a telemedicine or remote care program to manage patients with NVAF and prevent stroke, Employ telemedicine and remote care services to diagnose and manage patients with NVAF during the COVID-19 pandemic and beyond.

Go online to PeerView.com/ECU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss real-world applications of emerging data and innovative therapeutics, offering practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Describe when and how novel therapeutic agents in advanced bladder cancer can be used over multiple lines of treatment and across patient populations, Cite the latest safety and efficacy data on newer therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates and gene therapy across the spectrum of bladder cancer settings, Select novel therapeutics for the management of bladder cancer based on patient-related factors and preferences, Develop appropriate management plans that take into account unique adverse events associated with new immune-, targeted-, and antibody-, and gene therapy-based treatments for bladder cancer.

Go online to PeerView.com/HYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses treatment with IL-17 inhibitors in nonradiographic axial spondyloarthritis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of nonradiographic axial spondyloarthritis (nr-axSpA), Discuss the rationale for IL-17 inhibition as a treatment approach to axSpA, Summarize efficacy and safety data related to IL-17 inhibitors for the treatment of nr-axSpA, Apply anti-IL-17 therapy for the treatment of nr-axSpA in accordance with current evidence and individual patient needs.

Go online to PeerView.com/BCF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A new, expert-led MasterClass from PeerView and the Us TOO International Prostate Cancer Education & Support Network will provide guidance on individualizing treatment regimens for patients with prostate cancer and will address the latest clinical evidence and guidelines/expert consensus recommendations. The program will also offer information on relevant patient-, tumor-, and treatment-related factors, as well as how to handle patients’ specific needs and preferences. Upon completion of this activity, participants should be better able to: Review recent safety and efficacy data of emerging and available agents across the prostate cancer disease continuum (nmCRPC, mCSPC, mCRPC), including the latest evidence and expert recommendations for selection and sequencing of approved hormonal and chemotherapy options, Outline the latest clinical evidence for appropriate use of novel therapies (eg, PARP inhibitors and immunotherapy) in mCRPC, including monotherapy and combination approaches, Evaluate the latest genetic testing guidelines to better direct treatment decision-making throughout the prostate cancer disease continuum, Develop evidence-based, tailored treatment plans, including the option of clinical trial enrollment, for patients with prostate cancer, based on disease-, patient-, and treatment-specific factors.

Go online to PeerView.com/MME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelofibrosis (MF) is a rare myeloproliferative neoplasm which can lead to marrow fibrosis, neo-angiogenesis, and osteosclerosis causing progressive splenomegaly with or without hepatomegaly. Currently, the only potential cure for MF is hematopoietic cell transplantation (HCT). However, the emergence and validation of JAK inhibitors has impacted treatment decisions, including the timing of HCT, and newer evidence suggests that next-generation JAK inhibitors may also play a role in challenging treatment settings defined by failure of upfront JAK inhibitor therapy. Clinicians therefore should be prepared to develop truly personalized, newer therapeutic strategies for MF management that consider all available options—from targeted agents to supportive care, as well as HCT—and address the role of JAK inhibitors in patients who are transplant candidates and determine their role before and, possibly, after transplantation. In this activity based on a recent live web broadcast, a panel of experts describes the current therapeutic landscape of MF, including JAK inhibitors and HCT. They also review evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in MF. Upon completion of this activity, participants should be better able to: Describe modern diagnostic and prognostic models, as well as molecular and clinical features that are useful for capturing myelofibrosis (MF) presentations, including primary MF and post-PV/ET MF, Review the current therapeutic role of JAK inhibitors and allogeneic hematopoietic cell transplantation (HCT), including reduced-intensity transplant, in the management of MF, Cite recent safety and efficacy evidence supporting the use of first- and second-generation JAK inhibitors and other targeted agents in the management of MF, Integrate modern JAK inhibitor-based regimens into risk-adapted treatment plans for patients with symptomatic MF, including those who are eligible for allogeneic transplantation or as sequential options in the non-HCT setting.